These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26438560)

  • 21. Prognostic Value of Dynamic Susceptibility Contrast-Enhanced and Diffusion-Weighted MR Imaging in Patients with Glioblastomas.
    Çoban G; Mohan S; Kural F; Wang S; O'Rourke DM; Poptani H
    AJNR Am J Neuroradiol; 2015 Jul; 36(7):1247-52. PubMed ID: 25836728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent Diffusion Coefficient as a Predictive Biomarker for Survival in Patients with Treatment-Naive Glioblastoma Using Quantitative Multiparametric Magnetic Resonance Profiling.
    Kim BS; Kim ST; Kim JH; Seol HJ; Nam DH; Shin HJ; Lee JI; Kong DS
    World Neurosurg; 2019 Feb; 122():e812-e820. PubMed ID: 30391622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging.
    Møller S; Lundemann M; Law I; Poulsen HS; Larsson HB; Engelholm SA
    Acta Oncol; 2015; 54(9):1521-8. PubMed ID: 26203926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dixon-based fat-free MR-angiography compared to first pass and steady-state high-resolution MR-angiography using a blood pool contrast agent.
    Homsi R; Gieseke J; Kukuk GM; Träber F; Willinek WA; Schild HH; Hadizadeh DR
    Magn Reson Imaging; 2015 Nov; 33(9):1035-1042. PubMed ID: 26220860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
    Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
    AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
    Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
    Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
    Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and prognostic significance of non-enhancing cortical signal abnormality in glioblastoma.
    Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
    J Med Imaging Radiat Oncol; 2016 Feb; 60(1):66-73. PubMed ID: 26597591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.
    Wang K; Wang Y; Fan X; Wang J; Li G; Ma J; Ma J; Jiang T; Dai J
    Neuro Oncol; 2016 Apr; 18(4):589-97. PubMed ID: 26409566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma?
    Stensjøen AL; Berntsen EM; Mikkelsen VE; Torp SH; Jakola AS; Salvesen Ø; Solheim O
    World Neurosurg; 2017 May; 101():686-694.e4. PubMed ID: 28300718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study.
    Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ
    AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.
    Czarnek N; Clark K; Peters KB; Mazurowski MA
    J Neurooncol; 2017 Mar; 132(1):55-62. PubMed ID: 28074320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral heterogeneity of oxygen metabolism and neovascularization uncovers 2 survival-relevant subgroups of IDH1 wild-type glioblastoma.
    Stadlbauer A; Zimmermann M; Doerfler A; Oberndorfer S; Buchfelder M; Coras R; Kitzwögerer M; Roessler K
    Neuro Oncol; 2018 Oct; 20(11):1536-1546. PubMed ID: 29718366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: Multicenter intraindividual crossover comparison.
    Schneider G; Pasowicz M; Vymazal J; Seidl Z; Aschauer M; Konopka M; Bilecen D; Iezzi R; Ballarati C
    AJR Am J Roentgenol; 2010 Aug; 195(2):476-85. PubMed ID: 20651208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging.
    Yamasaki F; Sugiyama K; Ohtaki M; Takeshima Y; Abe N; Akiyama Y; Takaba J; Amatya VJ; Saito T; Kajiwara Y; Hanaya R; Kurisu K
    Eur J Radiol; 2010 Mar; 73(3):532-7. PubMed ID: 19250783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
    J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease.
    McGregor R; Vymazal J; Martinez-Lopez M; Neuwirth J; Salgado P; Beregi JP; Peduto A; de la Pena-Almaguer E; Slater GJ; Shamsi K; Parsons EC
    Eur J Radiol; 2008 Feb; 65(2):316-25. PubMed ID: 17499952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.